Independent research on the U.S. markets, Baptista Research

Baptista Research

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. 

We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Pfizer has intensified its oncology push through a major global licensing and collaboration agreement with Innovent Biologics (HKEX:1801), giving it access to 12 early-stage cancer programs in a deal worth up to $10.5 billion.</li><li>The agreement includes a $650 million upfront payment to Innovent and as much as $9.85 billion in milestone payments, with Innovent leading Phase 1 development before Pfizer assumes global development responsibilities.</li><li>The transaction follows Pfizer’s earlier licensing activity with China’s 3SBio and comes as global pharmaceutical companies increasingly tap China’s biotech ecosystem for antibody-drug conjugates, multi-specific antibodies, and differentiated oncology platforms.</li></ul>

Pfizer has intensified its oncology push through a major global licensing and collaboration agreement with Innovent Biologics (HKEX:1801), giving it access to 12 early-stage cancer programs in a deal worth up to $10.5 billion.The agreement includes a $650 million upfront payment to Innovent and as much as $9.85 billion in milestone payments, with Innovent leading Phase 1 development before Pfizer assumes global development responsibilities.The transaction follows Pfizer’s earlier licensing activity with China’s 3SBio and comes as global pharmaceutical companies increasingly tap China’s biotech ecosystem for antibody-drug conjugates, multi-specific antibodies, and differentiated oncology platforms.

Pfizer $10.5 Billion Buyout Target? Innovent Could Be The Cancer Pipeline Prize!

Pfizer Inc

Pfizer $10.5 Billion Buyout Target? Innovent Could Be The Cancer Pipeline Prize!